It is certainly a good Dividend King to buy in September.

Citadel, Ken Griffin's hedge fund, materially increased its stake in AbbVie; here's why you may want to follow that lead.

AbbVie and Abbott stand out as strong healthcare investments because they combine established businesses with long-term growth opportunities.

His AbbVie purchase was a big move into a high-yielding dividend stock.

Billionaire hedge fund manager Ken Griffin was in the news after he scooped up most of the public stock portfolio formerly held by Situational Awareness late last month. In what w ...

AbbVie is a global, research-driven biopharmaceutical company that develops therapies in the pharmaceutical stocks space. It discovers and commercializes advanced treatments for immunology, ...

AbbVie's flagship drug is bleeding revenue quarter after quarter, yet the company just handed shareholders another raise.

AbbVie had 10 therapies with sales of $1 billion or more each in 2025. The pharma giant has raised its dividends annually for 54 consecutive years. AbbVie has a large pipeline of mid- and late-stage ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Pharmaceutical giant AbbVie (NYSE: ABBV) made a bold move this past Monday when it announced its planned $10.9 billion acquisition of Apogee Therapeutics (NASDAQ: APGE). The deal would bring a ...

Choosing between a high-yield pharmaceutical powerhouse and a diversified healthcare leader requires looking at growth and stability. You must decide whether AbbVie(NYSE:ABBV) or Abbott ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...